p53-dependent ceramide response to genotoxic stress

Journal of Clinical Investigation

Volumn 102, Issue 2, 1998, Pages 329-339

  Dbaibo, Ghassan S ^a,c   Pushkareva, Marina Y ^a,d   Rachid, Rima A ^c   Alter, Nejemie ^a   Smyth, Miriam J ^a,b   Obeid, Lina M ^a,b   Hannun, Yusuf A ^a,e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d Liposome Corporation   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Ceramide; P53; Sphingolipids

Indexed keywords

CERAMIDE; DACTINOMYCIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL STRAIN HL 60; CELL STRAIN L 929; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA IRRADIATION; GENOTOXICITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STRESS;

EID: 0032528176     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1180     Document Type: Article

References (77)

1. Vogelstein, B., and K.W. Kinzler. 1992. p53 function and dysfunction. Cell. 70:523-526.
2. Canman, C.E., C.Y. Chen, M.H. Lee, and M.B. Kastan. 1994. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb. Symp. Quant. Biol. 59:277-286.
3. Picksley, S.M., and D.P. Lane. 1994. p53 and Rb: their cellular roles. Curr. Opin. Cell Biol. 6:853-858.
4. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science. 253:49-53.
5. Momand, J., G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237-1245.
6. Olson, D.C., V. Marechal, J. Momand, J. Chen, C. Romocki, and A.J. Levine. 1993. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene. 8:2353-2360.
7. Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1129-1136.
8. Scheffner, M., J.M. Huibregtse, R.D. Vierstra, and P.M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:495-505.
9. Picksley, S.M., and D.P. Lane. 1993. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays. 15:689-690.
10. Marchetti, A., F. Buttitta, S. Pellegrini, G. Merlo, A. Chella, C.A. Angeletti, and G. Bevilacqua. 1995. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn. Mol. Pathol. 4:93-97.
11. McCann, A.H., A. Kirley, D.N. Carney, N. Corbally, H.M. Magee, G. Keating, and P.A. Dervan. 1995. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer. 71:981-985.
12. Reifenberger, G., L. Liu, K. Ichimura, E.E. Schmidt, and V.P. Collins. 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:2736-2739.
13. Kuerbitz, S.J., B.S. Plunkett, W.V. Walsh, and M.B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:7491-7495.
14. Hartwell, L.H., and M.B. Kastan. 1994. Cell cycle control and cancer. Science. 266:1821-1828.
15. Atadja, P., H. Wong, I. Garkavtsev, C. Veillette, and K. Riabowol. 1995. Increased activity of p53 in senescing fibroblasts. Proc. Natl. Acad. Sci. USA. 92:8348-8352.
16. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
17. Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7:546-554.
18. Zhan, Q., I. Bae, M.B. Kastan, and A.J. Fornace, Jr. 1994. The p53-dependent gamma-ray response of GADD45. Cancer Res. 54:2755-2760.
19. Smith, M.L., I.-T. Chen, Q. Zhan, I. Bae, C.-Y. Chen, T.M. Gilmer, M.B. Kastan, P.M. O'Connor, and A.J. Fornace, Jr. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 266:1376-1380.
20. Mummenbrauer, T., F. Janus, B. Müller, L. Wiesmüller, W. Deppert, and F. Grosse. 1996. p53 protein exhibits 3′-to-5′ exonuclease activity. Cell. 85: 1089-1099.
21. Lane, D.P. 1992. p53, guardian of the genome. Nature. 358:15-16.
22. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
23. El-Deiry, W.S., J.W. Harper, P.M. O'Connor, V.E. Velculescu, C.E. Canman, J. Jackman, J.A. Pietenpol, M. Burrell, D.E. Hill, Y. Wang, et al. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169-1174.
24. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
25. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. 81:323-330.
26. Brugarolas, J., C. Chandrasekaran, J.I. Gordon, D. Beach, T. Jacks, and G.J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:552-557.
27. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:675-684.
28. Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370: 220-223.
29. Shen, Y., and T. Shenk. 1994. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kD protein or the cellular Bcl-2 protein. Proc. Natl. Acad. Sci. USA. 91:8940-8944.
30. Sabatini, P., S. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
31. Hannun, Y.A. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269:3125-3128.
32. 3-induced HL-60 cell differentiation. J. Biol. Chem. 265:15823-15831.
33. Jayadev, S., B. Liu, A.E. Bielawska, J.Y. Lee, F. Nazaire, M.Y.U. Pushkareva, L.M. Obeid, and Y.A. Hannun. 1995. Role for ceramide in cell cycle arrest. J. Biol. Chem. 270:2047-2052.
34. Dbaibo, G.S., M.Y. Pushkareva, S. Jayadev, J.K. Schwarz, J.M. Horowitz, L.M. Obeid, and Y.A. Hannun. 1995. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc. Natl. Acad. Sci. USA. 92:1347-1351.
35. Obeid, L.M., C.M. Linardic, L.A. Karolak, and Y.A. Hannun. 1993. Programmed cell death induced by ceramide. Science. 259:1769-1771.
36. Venable, M.E., J.Y. Lee, M.J. Smyth, A. Bielawska, and L.M. Obeid. 1995. Role of ceramide in cellular senescence. J. Biol. Chem. 270:30701-30708.
37. Kim, M., C. Linardic, L. Obeid, and Y. Hannun. 1991. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor α and γ-interferon: specific role in cell differentiation. J. Biol. Chem. 266:484-489.
38. Cifone, M.G., R. De Maria, P. Roncaioli, M.R. Rippo, M. Azuma, L.L. Lanier, A. Santoni, and R. Testi. 1994. Apoptotic signaling through CD95 (Fas/ Apo-1) activates an acidic sphingomyelinase. J. Exp. Med. 180:1547-1552.
39. Tepper, C.G., S. Jayadev, B. Liu, A. Bielawska, R. Wolff, S. Yonehara, Y.A. Hannun, and M.F. Seldin. 1995. Role of ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc. Natl. Acad. Sci. USA. 92:8443-8447.
40. Haimovitz-Friedman, A., C.C. Kan, D. Ehleiter, R.S. Persaud, M. McLoughlin, Z. Fuks, and R.N. Kolesnick. 1994. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 180: 525-535.
41. Smyth, M.J., D.K. Perry, J. Zhang, G.G. Poirier, Y.A. Hannun, and L.M. Obeid. 1996. prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of bcl-2. Biochem. J. 316:25-28.
42. Dbaibo, G.S., D.K. Perry, C.J. Gamard, R. Platt, G.G. Poirier, L.M. Obeid, and Y.A. Hannun. 1997. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med. 185: 481-490.
43. Hannun, Y.A., and C.M. Linardic. 1993. Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. Biochim. Biophys. Acta Bio-Membr. 1154:223-236.
44. Pushkareva, M., L.M. Obeid, and Y.A. Hannun. 1995. Ceramide: an endogenous regulator of apoptosis and growth suppression. Immunol. Today. 16: 294-297.
45. Foster, S.A., G.W. Demers, B.G. Etscheid, and D.A. Galloway. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:5698-5705.
46. Kaufmann, S.H., S. Desnoyers, Y. Ottaviano, N.E. Davidson, and G.G. Poirier. 1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:3976-3985.
47. Bielawska, A., C.M. Linardic, and Y.A. Hannun. 1992. Ceramide-mediated biology: determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs. J. Biol. Chem. 267: 18493-18497.
48. Bielawska, A., H.M. Crane, D. Liotta, L.M. Obeid, and Y.A. Hannun. 1993. Selectivity of ceramide-mediated biology: lack of activity of erythro-dihydroceramide. J. Biol. Chem. 268:26226-26232.
49. Bligh, E.G., and W.J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Phys. 37:911-917.
50. Preiss, J., C.R. Loomis, W.R. Bishop, R. Stein, J.E. Niedel, and R.M. Bell. 1986. Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras-and sis-transformed normal rat kidney cells. J. Biol. Chem. 261:8597-8600.
51. Rouser, G., S. Fleischer, and A. Yamamoto. 1970. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:494-496.
52. Trask, D.K., and M.T. Muller. 1988. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA. 85:1417-1421.
53. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
54. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
55. Alnemri, E.S., D.J. Livingston, D.W. Nicholson, G. Salvesen, N.A. Thornberry, W.W. Wong, and J. Yuan. 1996. Human ICE/CED-3 protease nomenclature. Cell. 87:171.
56. Lazebnik, Y.A., S.H. Kaufmann, S. Desnoyers, G.G. Poirier, and W.C. Earnshaw. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371:346-347.
57. Fernandes-Alnemri, T., G. Litwack, and E.S. Alnemri. 1994. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 β-converting enzyme. J. Biol. Chem. 269:30761-30764.
58. Tewari, M., L.T. Quan, K. O'Rourke, S. Desnoyers, Z. Zeng, D.R. Beidler, G.G. Poirier, G.S. Salvesen, and V.M. Dixit. 1995. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 81:801-809.
59. Nicholson, D.W., A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labele, Y.A. Lazebnik, et al. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:37-43.
60. Strum, J.C., G.W. Small, S.B. Pauig, and L.W. Daniel. 1994. 1-β-D-arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem. 269:15493-15497.
61. Zhang, J., N. Alter, J.C. Reed, C. Borner, L.M. Obeid, and Y.A. Hannun. 1996. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc. Natl. Acatl. Sci. USA. 93:5325-5328.
62. Bose, R., M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z. Fuks, and R.N. Kolesnick. 1996. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 82:405-414.
63. Jaffrézou, J., T. Levade, A. Bettaïeb, N. Andrieu, C. Bezombes, N. Maestre, S. Vermeersch, A. Rousse, and G. Laurent. 1996. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO (Eur. Mol. Biol. Organ.) J. 15:2417-2424.
64. Watts, J.D., M. Gu, A.J. Polverino, S.D. Patterson, and R. Aebersold. 1997. Fas-induced apoptosis of T cells occurs independently of ceramide generation. Proc. Natl. Acad. Sci. USA. 94:7292-7296.
65. Lowe, S.W., E.M. Schmitt, S.W. Smith, B.A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:847-849.
66. Tsang, N.M., H. Nagasawa, C. Li, and J.B. Little. 1995. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene. 10:2403-2408.
67. Slebos, R.J., M.H. Lee, B.S. Plunkett, T.D. Kessis, B.O. Williams, T. Jacks, L. Hedrick, M.B. Kastan, and K.R. Cho. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA. 91:5320-5324.
68. White, E. 1994. p53, guardian of Rb. Nature. 371:21-22.
69. Jayadev, S., H.L. Hayter, N. Andrieu, C.J. Gamard, B. Liu, R. Balu, M. Hayakawa, F. Ito, and Y.A. Hannun. 1997. Phospholipase A2 is necessary for tumor necrosis factor α-induced ceramide generation in L929 cells. J. Biol. Chem. 272:17196-17203.
70. Hannun, Y.A. 1996. Functions of ceramide in coordinating cellular responses to stress. Science. 274:1855-1859.
71. Allouche, M., A. Bettaieb, C. Vindis, A. Rousse, C. Grignon, and G. Laurent. 1997. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene. 14:1837-1845.
72. Martin, S.J., S. Takayama, A.J. McGahon, T. Miyashita, J. Corbeil, R.N. Kolesnick, J.C. Reed, and D.R. Green. 1995. Inhibition of ceramide-induced apoptosis by Bcl-2. Cell Death Differ. 2:253-257.
73. Jarvis, W.D., F.A. Fornari, Jr., J.L. Browning, D.A. Gewirtz, R.N. Kolesnick, and S. Grant. 1994. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J. Biol. Chem. 269:31685-31692.
74. Shiohara, M., W.S. El-Deiry, M. Wada, T. Nakamaki, S. Takeuchi, R. Yang, D.L. Chen, B. Vogelstein, and H.P. Koeffler. 1994. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:3781-3784.
75. Strasser, A., A.W. Harris, T. Jacks, and S. Cory. 1994. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:329-339.
76. Hannun, Y.A. 1997. Sphingolipid-Mediated Signal Transduction. R.G. Landes Company, Austin, TX. 188 pp.
77. Santana, P., L.A. Peña, A. Haimovitz-Friedman, S. Martin, D. Green, M. McLoughlin, C. Cordon-Cardo, E.H. Schuchman, Z. Fuks, and R. Kolesnick. 1996. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 86:189-199.